Home » GLAXOSMITHKLINE BEGINS TESTING NEW TECHNOLOGY TO PROTECT PATIENTS AGAINST COUNTERFEIT MEDICINE

GLAXOSMITHKLINE BEGINS TESTING NEW TECHNOLOGY TO PROTECT PATIENTS AGAINST COUNTERFEIT MEDICINE

March 23, 2006

GlaxoSmithKline has begun distributing a medicine tagged with radio frequency identification (RFID) technology as part of a pilot project to help protect patient safety.
Finanzen.net

KEYWORDS FDAnews Device Daily Bulletin

15Jun
Create a Quality Culture to Aid Risk Management: Dynamic Behaviors that Achieve Quality and Business Objectives
17Jun
Accelerate the Startup of Your Clinical Trials Without Sacrificing Quality: Common Pitfalls that Cause Delays and How to Avoid Them
22Jun
FDA’s Plan to Modernize the 510(k) Pathway: What Regulatory, Quality and Compliance Professionals Need to Know
13Jul
Decentralized Clinical Trials: Benefits of a Better Patient Experience
13Jul
CBER’s Five-Year Plan: Address the Agency’s New Priorities and Stay Compliant in a Post-COVID-19 World
14Jul
Demystifying AI in the Life Sciences Industry: What Regulatory, Quality and Compliance Professionals Need to Know

GLAXOSMITHKLINE BEGINS TESTING NEW TECHNOLOGY TO PROTECT PATIENTS AGAINST COUNTERFEIT MEDICINE

Upcoming Events

Create a Quality Culture to Aid Risk Management: Dynamic Behaviors that Achieve Quality and Business Objectives

Accelerate the Startup of Your Clinical Trials Without Sacrificing Quality: Common Pitfalls that Cause Delays and How to Avoid Them

FDA’s Plan to Modernize the 510(k) Pathway: What Regulatory, Quality and Compliance Professionals Need to Know

Decentralized Clinical Trials: Benefits of a Better Patient Experience

CBER’s Five-Year Plan: Address the Agency’s New Priorities and Stay Compliant in a Post-COVID-19 World

Demystifying AI in the Life Sciences Industry: What Regulatory, Quality and Compliance Professionals Need to Know

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Merck Snags $1.2 Billion U.S. Contract for Experimental COVID-19 Therapy

FDA Awards Amazon Subsidiary EUA for Direct-to-Consumer COVID-19 Test

BeiGene’s Brukinsa Makes Strong Showing in Leukemia Trial

Biden Orders Software Developers to List Third-Party Components

The Revised ICH E8: A Guide to New Clinical Trial Requirements